Mas Rahmah, - (2020) Government-Use License and Stem Cell-Based Pharmaceuticals Patent : Equitabla Access to Covid-19 Medication. Utopia Y Praxis Latinoamericana, 25 (7). pp. 94-110. ISSN 1316-5216

	Text (PEER REVIEW) 3b. Reviewer_Government-Use License.pdf Download (700kB)
	Text (FULL TEXT) 3. Government Use License and Steam Cell-Based Pharmaceuticals Patent_ Equitable Access to Covid-19 Medications.pdf Download (493kB)
	Text (SIMILARITY) 3a. TURNIITIN_Government-Use License and Stem Cell-Based Pharmaceuticals Patent- Equitable Access to Covid-19 Medications-2 (1).pdf Download (3MB)
	Text (KORESPONDENSI) 3C. KORESPONDENSI GOVERNMENT USE LICENSE....pdf Download (11MB)

Abstract

In response to the outbreak of the Covid-19 pandemic, some pharmaceutical companies have patented their drugs to combat it, including those based on stem cells. Questions about how to access such drugs will likely be raised because patent protection grants an exclusive right to the patent owner, to prevent someone else from benefiting from a large-scale price increase. The document will then review the regulation and practice of government use in Indonesia and the possibility of such a mechanism to access Covid-19 drugs.

Actions (login required)

View Item